Kodiak Sciences, Inc. (KOD)
88.12
+7.03
(+8.67%)
USD |
NASDAQ |
Oct 15, 16:00
88.19
+0.07
(+0.08%)
After-Hours: 20:00
Kodiak Sciences Research and Development Expense (Quarterly) : 56.08M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 56.08M |
| March 31, 2026 | 48.55M |
| December 31, 2025 | 45.49M |
| September 30, 2025 | 50.48M |
| June 30, 2025 | 42.76M |
| March 31, 2025 | 43.64M |
| December 31, 2024 | 31.77M |
| September 30, 2024 | 31.88M |
| June 30, 2024 | 32.51M |
| March 31, 2024 | 29.93M |
| December 31, 2023 | 46.63M |
| September 30, 2023 | 36.19M |
| June 30, 2023 | 66.96M |
| March 31, 2023 | 56.52M |
| December 31, 2022 | 55.99M |
| September 30, 2022 | 61.68M |
| June 30, 2022 | 73.74M |
| March 31, 2022 | 76.18M |
| Date | Value |
|---|---|
| December 31, 2021 | 75.60M |
| September 30, 2021 | 56.00M |
| June 30, 2021 | 45.40M |
| March 31, 2021 | 40.34M |
| December 31, 2020 | 37.36M |
| September 30, 2020 | 29.31M |
| June 30, 2020 | 20.56M |
| March 31, 2020 | 20.17M |
| December 31, 2019 | 12.83M |
| September 30, 2019 | 10.12M |
| June 30, 2019 | 8.838M |
| March 31, 2019 | 5.723M |
| December 31, 2018 | 6.851M |
| September 30, 2018 | 4.709M |
| March 31, 2018 | 3.642M |
| December 31, 2017 | 8.776M |
| September 30, 2017 | 3.148M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| AbbVie, Inc. | 2.344B |
| Mirum Pharmaceuticals, Inc. | 90.29M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |